About US
Contact us
-
Ackman's Valeant ties pay off yet again with Sprout buyBill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan ($AGN). And this time, it's an in2015/8/24
-
Approval system reform for drugs, medical instrumentsChina has decided to reform its appraisal and approval system for drugs and medical instruments with the aim of improving drug safety and quality and encouraging innovation. According to a guideline2015/8/21
-
GSK OTC push marred by super-sized recall of toothpasteThe decision of GlaxoSmithKline ($GSK) CEOAndrew Wittyto double down on consumer health products has not been very popular with some investors, who question the strategy of focusing on low-margin, hig2015/8/21
-
FDA official encourages makers of Low T drugs to work together on a single risks trialWhile data on the heart and stroke risks oftestosteroneenhancers have been mixed, theFDAhas held firm on its position that "Low T" drugs should be used only for medical conditions and not as a lifesty2015/8/21
-
CFDA Vice Minister Wu Zhen meets the delegation of Kenya's National Assembly Departmental Committee on HealthOn the afternoon of August 12, 2015, Wu Zhen, Vice Minister of China Food and Drug Administration (CFDA), met with the delegation of Kenya's National Assembly Departmental Committee on Health headed b2015/8/20
-
Amgen wraps up Aranesp, Enbrel marketing probe with $71M state-level settlementAmgen ($AMGN) is paying up to resolve claims that it broke the rules while marketing anemia drugAranespand anti-inflammatory blockbusterEnbrel. The company has settled with 48 states for $71 million,2015/8/20
-
Horizon puts forth its slate of new Depomed directorsHorizon ($HZNP) has criticized Depomed's ($DEPO) directors for refusing to come to the table, despite its attempts to "engage in good faith" over a combination of the two companies. Now, though, it's2015/8/20
-
FDA hammers Mylan sterile injectable plants for serious contamination issuesThe recent recall of 8 lots of injectable cancer drugs, some of which Mylan ($MYL) made for client Pfizer ($PFE), was just a prelude to anFDAwarning letter, it turns out. The agency today posted the l2015/8/19
-
Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partnersWho should serial buyer Allergan ($AGN) pick up next? It's the question on the minds of many industry watchers--including Evercore ISI analyst Umer Raffat, who polled investors last week. And while th2015/8/19
-
Will docs jump on new biosims? Survey shows they'll need some nudgingDrugmakers are well aware of the biosimilars threatening to steal sales and market share from some of the world's best-selling biologics. Doctors, though? Not so much, a new report suggests. Doctor2015/8/18